Jnana Therapeutics lures Janssen exec to be its new CMO and head of R&D
Boston, USA-based biotech start-up Jnana Therapeutics has appointed Dr George Vratsanos as its chief medical officer and head of research and development.
Dr Vratsanos brings over 20 years of experience in roles spanning translational medicine, late-stage therapeutics development, and medical affairs. He will be responsible for leading the Company’s research and development teams.
Prior to joining Jnana, Dr Vratsanos held several senior leadership roles at Janssen Pharmaceuticals, a unit of Johnson & Johnson (NYSE: JNJ). Most recently, he served as senior vice president translational science and medicine for the immunology therapeutic area, a division he formed to bring transformational new medicines and treatments to patients with immune diseases, including rare diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze